Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted therapy for alcohol use disorder and depression
ACTRN12626000316303Phase 2Not yet recruiting
- Sponsor
- Eastern Health
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in alcohol use disorder (AUD) and major depressive disorder (MDD), sponsored by Eastern Health. Primary endpoints: Recruitment feasibility (screened-to-enrolled participant ratio) and Recruitment duration feasibility. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
alcohol use disorder (AUD)major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12626000316303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000316303.